Table 1.
Baseline demographic and clinical characteristics of 177 mCRC patients.
| Characteristics | All Patients (n = 177) | |
|---|---|---|
| n | % | |
| Sex | ||
| Men | 102 | 57.6 |
| Women | 75 | 42.4 |
| Age(years) | ||
| Median (range) | 60 (32–82) | |
| <65 | 121 | 68.4 |
| ≥65 | 56 | 31.6 |
| Site of primary disease* | ||
| Left-sided | 82 | 46.3 |
| Right-sided | 36 | 20.3 |
| Rectum | 59 | 33.3 |
| Gene mutation status | ||
| RAS/BRAF wild-type | 84 | 47.5 |
| RAS mutant | 88 | 49.7 |
| BRAF mutant | 5 | 2.8 |
| MMR status | ||
| pMMR | 174 | 98.3 |
| dMMR | 3 | 1.7 |
| Site of metastases† | ||
| Lung limited | 35 | 19.8 |
| Liver limited | 77 | 43.5 |
| Liver and lung | 36 | 20.3 |
| Other | 29 | 16.4 |
| Primary tumor resection | ||
| Yes | 154 | 87 |
| No | 23 | 13 |
| Metastasectomy | ||
| Liver | 26 | 14.7 |
| Lung | 10 | 5.6 |
| Liver and lung | 1 | 0.5 |
| No resection | 141 | 79.7 |
| Treatment line of regorafenib | ||
| Third-line | 114 | 64.4 |
| Forth or late-line | 63 | 35.6 |
| Previous biologics treatment# | ||
| anti-EGFR | 65 | 36.7 |
| anti-VEGF | 138 | 77.9 |
| Starting dose(mg) | ||
| 80 | 94 | 53.1 |
| 120 | 83 | 46.9 |
| Final dose(mg) | ||
| ≤80 | 155 | 87.6 |
| 120 | 18 | 15.5 |
pMMR, proficient mismatch repair; dMMR, deficient mismatch repair.
*Right-sided included tumors from cecal to two thirds of proximal transverse colon; left-sided represented tumors from one third of distal transverse colon to rectum (not including rectum).
†According to the site of metastases, patients were divided into four groups: (1) liver limited MET; (2) lung limited MET; (3) liver and lung MET (4) other MET.
#Anti-EGFR, Cetuximab or panitumumab; Anti-VEGF, Bevacizumab.